Antiproliferative agents. Similarities between tumour growth and benign neointimal
proliferation introduced the concept that immunosuppressant and cytotoxic agents might be …

The advent of intravascular stenting dramatically reduced the incidence of restenosis among
patients undergoing percutaneous transluminal coronary angioplasty. However, a …

Drug-eluting stents (DES) have entered the arena and are about to changed the landscape
of Interventional Cardiology. Today, the number of agents under preclinical and clinical …

Despite the success of drug-eluting stents (DES) in reducing restenosis and the need for
target vessel revascularization, several deficiencies have been unraveled since their first …

ARE DESs EFFECTIVE? Restenosis, the Achilles heel of both balloon angioplasty and
stenting with BMS, with rates in published series of nearly 50% and 25%, respectively, was …

OBJECTIVE To review the pathogenesis of in-stent restenosis and the evolution of drug-
eluting stents (DES). DATA SOURCES Using the search terms sirolimus, paclitaxel, and …

In-stent restenosis (ISR) caused by neointimal hyperplasia is the major drawback after
percutaneous coronary intervention (PCI) for obstructive coronary disease, occurring in up to …

Drug-eluting stents: the beginning of the end of restenosis? - Abstract - Europe PMC Sign in |
Create an account https://orcid.org Europe PMC Menu About Tools Developers Help Contact …

Coronary stent implantation has become a well established therapy in the management of
coronary artery disease (CAD). Although the Stent Restenosis Study (STRESS) and Belgium …

One of the major advancements in interventional cardiology has been the introduction of
drugeluting stents (DES). By incorporating anti-proliferative agents onto the surface of the …